首页|期刊导航|癌症生物学与医学（英文版）|Optimal immunotherapy duration in advanced NSCLC:defining the ideal treatment window

Optimal immunotherapy duration in advanced NSCLC:defining the ideal treatment window

Kaibo Ding Dujiang Liu Xinyue Li Zhongsheng Peng Lin Zhu Yanjun Xu

癌症生物学与医学（英文版）2025，Vol.22Issue(3)：284-294,11.

癌症生物学与医学（英文版）2025，Vol.22Issue(3)：284-294,11.DOI:10.20892/j.issn.2095-3941.2024.0457

Optimal immunotherapy duration in advanced NSCLC:defining the ideal treatment window

Kaibo Ding ¹Dujiang Liu ¹Xinyue Li ¹Zhongsheng Peng ²Lin Zhu ³Yanjun Xu¹

作者信息

1. Department of Medical Thoracic Oncology,Zhejiang Cancer Hospital,Hangzhou Institute of Medicine(HIM),Chinese Academy of Sciences,Hangzhou 310022,China||Postgraduate Training Base Alliance of Wenzhou Medical University(Zhejiang Cancer Hospital),Hangzhou 310022,China
2. Meizhou People's Hospital(Huangtang Hospital),Meizhou 514000,China
3. Department of Medical Thoracic Oncology,Zhejiang Cancer Hospital,Hangzhou Institute of Medicine(HIM),Chinese Academy of Sciences,Hangzhou 310022,China
折叠

摘要

关键词

Immune checkpoint inhibitors/immunotherapy/non-small cell lung cancer/duration of treatment/immunotherapy rechallenge

Key words

Immune checkpoint inhibitors/immunotherapy/non-small cell lung cancer/duration of treatment/immunotherapy rechallenge

引用本文复制引用

Kaibo Ding,Dujiang Liu,Xinyue Li,Zhongsheng Peng,Lin Zhu,Yanjun Xu..Optimal immunotherapy duration in advanced NSCLC:defining the ideal treatment window[J].癌症生物学与医学（英文版）,2025,22(3):284-294,11.

基金项目

This study was supported by the Natural Scientific Foundation of Zhejiang Province,China(Grant No.LTGY23H160007). （Grant No.LTGY23H160007）

癌症生物学与医学（英文版）

ISSN：2095-3941

访问量1

下载量0

段落导航